Cannabis, Drug Effects
Conditions
Keywords
Cannabidiol
Brief summary
This study will evaluate the pharmacokinetic and pharmacodynamic effects of oral Cannabidiol (with or without low levels of THC), under acute and chronic dosing conditions.
Detailed description
Participants (N=60), will be randomized to 1 of 3 oral dosing conditions that include: 100mg CBD/3.7mg THC (0.39% THC), 100mg CBD/2.8mg THC (0.3% THC), or 100mg CBD/0mg THC (0.0% THC). Participants will first complete an 8-hour drug administration session and after this initial session, participants will take participants' assigned study drug for the next 14 days at home, twice daily (participants will visit the lab on days 2, 7, and 14). Participants will return on day 21 (after 1 week washout) for a final visit. During the 8-hour session and visits occurring during the following 21 days, participants will provide biospecimens (urine, blood, oral fluid, hair) which will be tested for cannabinoid concentrations. Pharmacodynamic assessments (subjective and cognitive effects) will also be assessed during these visits.
Interventions
DRUGCBD
CBD will be orally ingested
DRUGTHC
THC will be orally ingested
Sponsors
Substance Abuse And Mental Health Administration
Canopy Growth Corporation
Johns Hopkins University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
dosing will be double-blind
Intervention model description
Participants (N=60), will be randomized to 1 of 3 oral dosing conditions that include: 100mg CBD/3.7mg THC (0.39% THC), 100mg CBD/2.8mg THC (0.3% THC), or 100mg CBD/0mg THC (0.0% THC).
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Have provided written informed consent 2. Be between the ages of 18 and 55 3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests 4. Test negative for recent cannabis use in urine at the screening visit and again upon admission for each experimental session 5. Test negative for other drugs of abuse, including alcohol at the screening visit and upon arrival for each experimental session 6. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission. 7. Have a body mass index (BMI) in the range of 19 to 36 kg/m2 8. Have head hair that is at least 4 cm (approximately one and a half inches) in length on the back of the head. 9. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg 10. Report prior experience using cannabis or CBD. 11. Have not donated blood in the prior 30 days. 12. Have a smartphone capable of downloading/operating the Redcap mobile application.
Exclusion criteria
1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the screening visit. 2. History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures. 3. Use of an over-the-counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of study entry; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. 4. Use of a prescription medication (with the exception of birth control prescriptions) within 14 days of study entry; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. This includes any medication metabolized via CYP2D6, CYP2C9, CYP2B10, or which induce/inhibit CYP3A4 enzymes. 5. Use of hemp seeds or hemp oil in any form in the past 3 months. 6. Use of dronabinol (Marinol) within the past 6 months. 7. History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples. 8. History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina). 9. Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing. 10. Epilepsy or a history of seizures. 11. Individuals who have a recent history of traumatic brain injury diagnosed by CT/MRI and have current sequela from prior brain injury, as determined by the study physician 12. Individuals with anemia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Urine cannabinoids | Day 1, 2, 7, 14, and 21 | Concentration of cannabinoids will be measured in urine (unit of measurement: nanograms/mL) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Subjective drug effects as assessed by the Drug Effect Questionnaire | Day 1 | Subjective drug effect ratings (0-100) will be collected with the Drug Effect Questionnaire, with 0 being no effect and 100 being maximum effect. |
| Blood cannabinoids | Day 1, 2, 7, 14, and 21 | Concentration of cannabinoids will be measured in blood (unit of measurement: nanograms/mL) |
| Oral Fluid cannabinoids | Day 1, 2, 7, 14, and 21 | Concentration of cannabinoids will be measured in oral fluid (unit of measurement: nanograms/mL) |
Countries
United States
Outcome results
None listed